Pfizer and BioNTech will test an omicron-specific COVID-19 vaccine in adult trials
Published
Pfizer and BioNTech will conduct three simultaneous trials in adults to determine if an omicron-specific vaccine is more effective than current shots.
Published
Pfizer and BioNTech will conduct three simultaneous trials in adults to determine if an omicron-specific vaccine is more effective than current shots.
Investors appear to be concerned about Pfizer's and BioNTech's head start in developing an omicron-specific vaccine.
Pfizer and BioNTech have started a clinical trial for their Omicron-specific COVID-19 vaccine.